778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma

Authors :: Gino K In
James Larkin
Yazan Samhouri
Marcus Butler
Victoria Atkinson
Jeffrey Chou
Juan Martin-Liberal
Patrick Terheyden
Sajeve Thomas
Wen Shi
Xiao Wu
Andrew S Poklepovic
Young Hong
Giri Sulur
Friedrich Graf Finckenstein
John B Haanen
Andrew JS Furness
Philip Lammers
Ryan H Nguyen
Idit Peretz
Source :: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Publication Year :: 2023
Publisher :: BMJ Publishing Group, 2023.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools